Letter to the Editor Regarding Esophageal Dysfunction and Systemic Sclerosis: Drugs Should be Kept in Mind

David Bernal-Bello; David Serantes-Gómez; Aida Izquierdo-Martínez; Alejandro Morales-Ortega; Miguel Ángel Duarte-Millán; Begoña Frutos-Pérez

doi:10.1007/s40744-022-00459-4

Letter to the Editor Regarding Esophageal Dysfunction and Systemic Sclerosis: Drugs Should be Kept in Mind

Rheumatol Ther. 2022 Aug;9(4):1237-1240. doi: 10.1007/s40744-022-00459-4. Epub 2022 Jun 18.

Authors

David Bernal-Bello¹, David Serantes-Gómez², Aida Izquierdo-Martínez², Alejandro Morales-Ortega^{2

3}, Miguel Ángel Duarte-Millán², Begoña Frutos-Pérez²

Affiliations

¹ Department of Internal Medicine, Hospital Universitario de Fuenlabrada, Camino del Molino, 2. 28942, Fuenlabrada, Madrid, Spain. david.bernal@salud.madrid.org.
² Department of Internal Medicine, Hospital Universitario de Fuenlabrada, Camino del Molino, 2. 28942, Fuenlabrada, Madrid, Spain.
³ Department of Medicine, Universidad de Alcalá, Madrid, Spain.

No abstract available

Keywords: Barrett’s esophagus; Drugs; Esophageal adenocarcinoma; Esophageal dysfunction; Gastroesophageal reflux disease; Scleroderma; Systemic sclerosis; Therapy.

Publication types

Letter